In vivo effects of a Ginkgo biloba extract on platelet activating factor metabolism in two asymptomatic HIV-infected patients

European Journal of Inflammation

Volumn 9, Issue 2, 2011, Pages 107-116

  Tsoupras, Alexandros B ^a   Chini, M ^b   Tsogas, N ^b   Mangafas, N ^b   Demopoulos, C A ^a   Lazanas, M C ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b RED CROSS HOSPITAL   (Greece)

Author keywords

Ginkgo biloba extract; Ginkgolides; HIV infection; Na ve patients; PAF metabolism; Platelet activating factor (PAF)

Indexed keywords

GINKGO BILOBA EXTRACT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; ASYMPTOMATIC INFECTION; BIOSYNTHESIS; CASE REPORT; CD4 LYMPHOCYTE COUNT; DISEASE DURATION; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IN VIVO STUDY; LEUKOCYTE; MALE; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; RECOMMENDED DRUG DOSE; VIRUS LOAD;

EID: 81855185817     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1100900204     Document Type: Article

References (30)

1. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L: chemistry, efficacy, safety, and uses. J Food Sci 2008; 73:14-9.
2. Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 2002; 67:235-57. (Pubitemid 34880132)
3. Zhou W, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. Cardiovasc Drug Rev 2004; 22:309-19. (Pubitemid 40123300)
4. DeFeudis FV, Papadopoulos V, Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam Clin Pharmacol 2003; 17:405-17. (Pubitemid 36920641)
5. Braquet, P. The ginkgolides: potent platelet-activating factor antagonists isolated from Ginkgo biloba L: chemistry, pharmacology and clinical applications. Drugs Future 1987; 12:643-99. (Pubitemid 17110888)
6. Demopoulos CA, Pinckard RN, Hanahan DJ. Platelet-activating factor, evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biologic Chem 1979; 254:9355-58. (Pubitemid 10248704)
7. Demopoulos CA, Karantonis HC, Antonopoulou S. Platelet activating factor - a molecular link between atherosclerosis theories. Eur J Lipid Science Technol 2003; 105:705-16. (Pubitemid 37533028)
8. Tsoupras AB, Iatrou C, Frangia C, Demopoulos CA. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets 2009; 9:390-9.
9. Doublier S, Zennaro C, Spatola T, Lupia E, Bottelli A, Deregibus MC, Carraro M, Conaldi PG, Camussi G. HIV-1 Tat reduces nephrin in human podocytes: a potential mechanism for enhanced glomerular permeability in HIV-associated nephropathy. AIDS 2007; 21:423-32.
10. Perry SW, Hamilton JA, Tjoelker LW, et al. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem 1998; 273:17660-64. (Pubitemid 28355104)
11. Biancone L, Cantaluppi V, Boccellino M, Bussolati B, Del Sorbo L, Conaldi PG, Albini A, Toniolo A, Camussi G. Motility induced by human immunodeficiency virus-1 Tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999; 155:1731-39.
12. Martin M, Serradji N, Dereuddre-Bosquet N, et al. PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages. Antimicrob Agents Chemother 2000; 44:3150-54.
13. Tsoupras AB, Chini M, Tsogas N, et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? AIDS Res Hum Retroviruses 2008; 24:1079-86.
14. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Cl Lab Sci 2003; 40:643-72. (Pubitemid 37491708)
15. Snyder F. Platelet-activating factor and its analogs: metabolic pathways and related intracellular processes. Biochim Biophys Acta 1995; 1254:231-49.
16. Francescangeli E, Boila A, Goracci G. Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex. Neurochem Res 2000; 25:705-13. (Pubitemid 30422005)
17. Snyder F. CDP-choline: alkylacetylglycerol choline phosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor. Biochim Biophys Acta 1997; 1348:111-6. (Pubitemid 27467083)
18. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987; 262:4215-22. (Pubitemid 17102639)
19. Squinto SP, Braquet P, Block AL, Bazan NG. Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes. J Mol Neurosci 1990; 2:79-84.
20. Lima RG, Moreira L, Paes-Leme J, Barreto-de-Souza V, Castro-Faria-Neto HC, Bozza PT, Bou-Habib DC. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. AIDS Res Hum Retroviruses 2006; 22:763-9. (Pubitemid 44735003)
21. Tsoupras AB, Fragopoulou E, Nomikos T, Iatrou C, Antonopoulou S, Demopoulos CA. Characterization of the de novo biosynthetic enzyme of platelet activating factor, DDT-insensitive cholinephosph otransferase, of human mesangial cells. Mediators Inflamm 2007; 2007:27683.
22. Tsantila N, Tsoupras AB, Fragopoulou E, Antonopoulou S, Iatrou C, Demopoulos CA. In vitro and in vivo effects of statins on platelet activating factor and its metabolism. Angiology 2010; Epub ahead of print.
23. Bradford MM. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
24. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37:911-7.
25. Antonopoulou S, Demopoulos CA, Iatrou C, Moustakas G, Zirogiannis P. Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney. Int J Biochem 1994; 26:1157-62.
26. Chini M, Tsoupras AB, Mangafas N, et al. Platelet Activating Factor (PAF)-Metabolism in Blood of HIV Infected, Naïve Patients and Healthy Controls. 48th IDSA Annual Meeting, Vancouver 2010; 1087.
27. Zou W, Kim BO, Zhou BY, Liu Y, Messing A, He JJ. Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. Am J Pathol 2007; 171:1923-35.
28. Lee JS, Hattori M, Kim J. Inhibition of HIV-1 protease and RNase H of HIV-1 reverse transcriptase activities by long chain phenols from the sarcotestas of Ginkgo biloba. Planta Med 2008; 74:1320.
29. Tsoupras AB, Chini M, Tsogas N, Mangafas N, Stamatakis G, Antonopoulou S, Demopoulos CA, Lazanas MC. Effects of Highly Active Antiretroviral Therapy (HAART) on Platelet Activating Factor (PAF) metabolism in HIV-infected patients: in vivo results. J Int AIDS Soc 2008; 11:1758-2652.
30. Khovidhunkit W, Memon RA, Shigenaga JK, Pang M, Schambelan M, Mulligan K, Feingold KR, Grunfeld C. Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Metabolism 1999; 48:1524-31.